ALAMEDA, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN), maker of advanced imaging systems designed to accelerate drug
discovery and development, today announced that David W. Carter, chairman and
chief executive officer, and Pamela Reilly Contag, Ph.D., president, will
present at the Thomas Weisel Partners 2005 Healthcare Conference to be held
September 7-9 at The Four Seasons Hotel in Boston, Massachusetts.
Xenogen's presentation will take place at 9:45 a.m. Eastern Time on
Friday, September 9, 2005. There will be a live audio webcast of the
presentation, which will be accessible through a link posted on the investor
relations section of Xenogen's website at http://www.xenogen.com. The webcast will
be available for replay on Xenogen's website for two weeks through September
23, 2005.
About Xenogen Corporation
Xenogen Corporation is a leading biotechnology company offering an
integrated suite of biophotonic real-time in vivo imaging and genetic
modification technologies that can help expedite drug discovery and
development, and significantly reduce the cost and time to market for new
therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and
monitor biological processes within living mammals, at the molecular level, in
real time. The technology provides higher quality in vivo data earlier in the
drug discovery and development process. VivoVision(TM) Solutions improve
discovery and pre-clinical research in multiple therapeutic areas.
VivoVision(TM) Biosciences represents more than 15 years of experience in the
creation and characterization of animal models, including genetic
modifications, comprehensive phenotyping, compound profiling and custom design
and production of light producing cells, microorganisms and animals.
More information is available at http://www.xenogen.com. Xenogen(R), Living
Image(R), VivoVision(TM) and IVIS(R) are trademarks of Xenogen Corporation.
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
William A. Albright, Chief Financial Officer
of Xenogen Corporation, +1-510- 291-6100
|
